The CHMP positive opinion is a transformative regulatory milestone that significantly increases the probability of European approval and Menarini-led launch in late 2026. Key upcoming catalysts: EC final decision, PREVAIL interim analysis (Q1 2027), RUBENS topline (YE 2026), and a potential Alzheimer's trial start. Monitor the Investor Day webcast for strategic details.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 5 $27.42entry
- T+1 · 3mo ago +0.91%α +1.07% · $27.67
- T+5 · 3mo ago +1.50%α +1.14% · $27.83
- T+20 · 3mo ago −6.67%α −6.07% · $25.59
- T+60 · 19d ago −24.29%α −24.23% · $20.76
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NewAmsterdam Pharma reported Q2 2026 results alongside the announcement that the CHMP has adopted a positive opinion recommending marketing authorization for obicetrapib (Ubeslo) and obicetrapib/ezetimibe FDC (Evlarco) in Europe, the most significant catalyst to date. Net loss widened to $64.1M from $17.4M a year ago on higher R&D costs and non-recurring Menarini milestone revenue in the prior-year period, but cash remains ample at $678.3M.
Key Facts
- CHMP positive opinion for obicetrapib 10 mg and FDC with ezetimibe; European Commission decision expected in 2H26
- Cash, cash equivalents and marketable securities of $678.3M at June 30, 2026
- Net loss of $64.1M in Q2 2026 vs $17.4M in Q2 2025
- Revenue of $3.7M vs $19.1M prior year (prior-year included $16.1M development cost contribution from Menarini)
- PREVAIL interim analysis planned for Q4 2026 with result in Q1 2027
- RUBENS Phase 3 topline data expected by year-end 2026
- Investor Day held on August 5, 2026
Financial Impact
Positive CHMP opinion substantially de-risks European approval; potential peak sales in Europe for obicetrapib are not disclosed but the addressable market includes >30M under-treated patients in the U.S. alone. Near-term financials are secondary to regulatory and clinical milestones.
Risk Factors
- European Commission may not follow the CHMP recommendation, though this is rare
- PREVAIL CVOT failure or underwhelming interim results could significantly impair the asset's value
- Commercial execution risk if approved, despite Menarini partnership
- Cash burn of ~$70M per six months provides runway but could necessitate future financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-333827 |
| Document: nams-20260805.htm | 0001193125-26-333827 |
| Document: 0001193125-26-333827-index-headers.html | 0001193125-26-333827 |
| Document: 0001193125-26-333827-index.html | 0001193125-26-333827 |
| Document: 0001193125-26-333827.txt | 0001193125-26-333827 |
| 8-K Data (Synthetic) | 0001193125-26-333827 |
Track record
8 reports on NAMS
3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +7.23% at T+5 after the Sep 22, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $18.89 to $18.90 Now $19.46 +3.02% ▲ +0.05% −0.26% vs SPY
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $20.93 to $18.89 Now $19.46 −7.02% ▼ −9.75% −5.34% vs SPY
- Sep 29, 20266w ago 8-K Neutral 4/10 Entry $23.81 to $24.32 Now $19.46 −18.27% ▲ +2.14% +2.35% vs SPY
- Sep 22, 20267w ago SC 13D/A Bullish 5/10 Entry $22.68 to $22.74 Now $19.46 −14.20% ▲ +0.26% +0.35% vs SPY
- Sep 15, 20268w ago Insider Buy Bullish 5/10 Entry $21.18 to $21.93 Now $19.46 −8.12% ▲ +3.54% +2.41% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 Viewing Entry $27.42 to $27.67 Now $19.46 −29.03% ▲ +0.91% +1.07% vs SPY
- Jul 24, 202616w ago 8-K Bullish 7/10 Entry $29.64 to $30.22 Now $19.46 −34.35% ▲ +1.96% +1.94% vs SPY
- Apr 8, 202631w ago Press Release Neutral 5/10 Entry $34.01 to $35.07 Now $19.46 −42.78% ▲ +3.12% +2.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers